Merck provided substantial evidence of safety and effectiveness for the approval of bezlotoxumab in June 2016 to the FDA, and the administration’s Antimicrobial Drugs Advisory Committee voted 10 to...
Today's opportunity for Indian companies in biosimilars is not much different from that of the generics industry in 1984. According to Ministry of Commerce and Industry, India’s pharmaceutical export segment has more than doubled from $ 7.8 billion in 2008 to $ 16.5 billion in 2014. With biologic treatments int...
Find MoreBoston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...
Find MoreThe recent outbreak of Dengue in Asia has brought forward the threat of mosquito bite into the spotlight again. Dengue is a kind of viral infection caused by mosquito bite, and the disease has now become a threat to about 390 million people, as these many are estimated to be infected each year. This incidence of inf...
Find MoreSun Pharma & ICGEB announce exclusive collaboration to develop novel dengue vaccine International Centre for Genetic Engineering and Biotechnology (ICGEB) and Sun Pharma Ltd. announced their new collaboration for development of a dengue vaccine, targeted against all the four serotypes of Dengue virus that cause ...
Find MoreFDA Approves Janssen's STELARA for the Treatment of Adults With Moderately to Severely Active Crohn’s Disease Janssen Biotech Inc. received approval from the U.S. FDA for STELARA (ustekinumab), used for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). The drug is for the ...
Find MoreUS FDA grants approval for Novartis' Ilaris to treat Periodic Fever Syndromes Novartis received approval to market its Periodic Fever Syndrome drug Ilaris (cancakinumab). The drug targets the syndrome, and will be used to treat a group of diseases that cause serious recurrent fever and pathogenic inflammation throug...
Find MoreCollaboration between Sygnis AG and ECACC for licensing and distribution of Caco-2 cell line Sygnis AG enters into a collaboration agreement with ECACC to significantly expand Sygnis' Caco-2 business. Under the collaboration, ECACC will organize that companies obtain the license for the use of the Caco-2 cell line f...
Find MoreA vaccine is a biological cocktail composed of inactive microorganisms that are either attenuated or dead. It has been found that human immune system maintains a memory of disease causing agents to save the body from the next attack. But vaccines till date are known to treat only specific type of ailments. To ...
Find MoreDelveInsight, the leading market research and consulting company has added new report “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: · CAR-T cell Therapy Pipeline scenario · Collaborations &...
Find MoreUremic Pruritusis also known as chronic kidney disease-associated pruritus (CKD-aP), is a chronic it.....
Find MoreThe gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....
Find MoreIntra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....
Find MoreAcute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes low blood oxygen......
Find MoreRheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....
Find MoreCell therapies now are often recommended to treat cancer in several ways, out of which CAR T-cell th.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.